Synopsis
0
KDMF
0
VMF
0
Europe
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
API SUPPLIERS
Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.
Click Us!
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34254
Submission : 2019-11-18
Status :
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]South Africa
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Clofazimine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Clofazimine, including repackagers and relabelers. The FDA regulates Clofazimine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Clofazimine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Clofazimine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Clofazimine supplier is an individual or a company that provides Clofazimine active pharmaceutical ingredient (API) or Clofazimine finished formulations upon request. The Clofazimine suppliers may include Clofazimine API manufacturers, exporters, distributors and traders.
click here to find a list of Clofazimine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Clofazimine DMF (Drug Master File) is a document detailing the whole manufacturing process of Clofazimine active pharmaceutical ingredient (API) in detail. Different forms of Clofazimine DMFs exist exist since differing nations have different regulations, such as Clofazimine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Clofazimine DMF submitted to regulatory agencies in the US is known as a USDMF. Clofazimine USDMF includes data on Clofazimine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Clofazimine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Clofazimine suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Clofazimine Drug Master File in Japan (Clofazimine JDMF) empowers Clofazimine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Clofazimine JDMF during the approval evaluation for pharmaceutical products. At the time of Clofazimine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Clofazimine suppliers with JDMF on PharmaCompass.
A Clofazimine CEP of the European Pharmacopoeia monograph is often referred to as a Clofazimine Certificate of Suitability (COS). The purpose of a Clofazimine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Clofazimine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Clofazimine to their clients by showing that a Clofazimine CEP has been issued for it. The manufacturer submits a Clofazimine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Clofazimine CEP holder for the record. Additionally, the data presented in the Clofazimine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Clofazimine DMF.
A Clofazimine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Clofazimine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Clofazimine suppliers with CEP (COS) on PharmaCompass.
A Clofazimine written confirmation (Clofazimine WC) is an official document issued by a regulatory agency to a Clofazimine manufacturer, verifying that the manufacturing facility of a Clofazimine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Clofazimine APIs or Clofazimine finished pharmaceutical products to another nation, regulatory agencies frequently require a Clofazimine WC (written confirmation) as part of the regulatory process.
click here to find a list of Clofazimine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Clofazimine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Clofazimine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Clofazimine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Clofazimine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Clofazimine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Clofazimine suppliers with NDC on PharmaCompass.
Clofazimine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Clofazimine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Clofazimine GMP manufacturer or Clofazimine GMP API supplier for your needs.
A Clofazimine CoA (Certificate of Analysis) is a formal document that attests to Clofazimine's compliance with Clofazimine specifications and serves as a tool for batch-level quality control.
Clofazimine CoA mostly includes findings from lab analyses of a specific batch. For each Clofazimine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Clofazimine may be tested according to a variety of international standards, such as European Pharmacopoeia (Clofazimine EP), Clofazimine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Clofazimine USP).
LOOKING FOR A SUPPLIER?
